Personal Information
Name
KISHIMOTO Tadamitsu
Section
Section II, Seventh Subsection
Date of Election
1995/12/12
Speciality
Immunology
Selected Bibliography
- Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi, and T. Kishimoto. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76, 1986.
- Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988.
- Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. Cloning and expression of human interleukin 6 (BSF-2/IFNb2) receptor. Science 241: 825-828, 1988.
- Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58: 573-581, 1989.
- Hibi, M., M. Murakami, M. Saito, T. Hirano, T. Taga, and T. Kishimoto. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63: 1149-1157, 1990.
- Akira, S., H. Isshiki, T. Sugita, O. Tanabe, S. Kinoshita, Y. Nishio, T. Nakajima, T. Hirano, and T. Kishimoto. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 9: 1897-1906, 1990.
- Akira, S., Y. Nishio, M. Inoue, X. Wang, S. Wei, T. Matsusaka, K. Yoshida, T. Sudo, M. Naruto, and T. Kishimoto. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63-71, 1994.
- Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, S. Akira, and T. Kishimoto. Structure and function of a new STAT-induced STAT inhibitor-1. Nature 387: 924-929, 1997.
- Nishimoto, N., M. Sasai, Y. Shima, M. Nakagawa, T. Matsumoto, T. Shirai, T. Kishimoto, and K. Yoshizaki. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56-61, 2000.
- Nishimoto, N., K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, J. Hashimoto, J. Azuma, and T. Kishimoto. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50: 1761-1769, 2004.
- Yokota, S., T. Miyamae, T. Imagawa, N. Iwata, S. Katakura, M. Mori, P. Woo, N. Nishimoto, K. Yoshizaki, and T. Kishimoto. Therapeutic efficacy of humanized recombinant anti-IL-6 receptor antibody for children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52: 818-825, 2005.
- Kishimoto, T. Interleukin-6: From basic science to medicine, 40 years in immunology. Annu. Rev. Immunol. 23: 1-21, 2005.
- Tanaka, T., Narazaki, M., and Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspective Biol. 6, 2014.
- Higa, M., Oka, M., Fujihara, Y., Masuda, K., Yoneda, Y., and Kishimoto, T. Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. Proc. Natl. Acad. Sci. USA 115(6): E1214-E1220, 2018.
- Gemechu, Y., Millrine, D., Hashimoto, S., Prakash, J., Sanchenkova, K., Metwally, H., Gyanu, P., Kang, S.J., and Kishimoto, T. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proceedings of the National Academy of Sciences of the United States of America 115: 11802-11807, 2018.
- Kang, S., Narazaki, M., Metwally, H., Kishimoto, T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 4;217(5): e20190347, May 2020.
- Kang, S., Tanaka, T., Inoue, H., Ono, C., Hashimoto, S., Kioi, Y., Matsumoto, H., Matsuura, H., Matsubara, T., Shimizu, K., Ogura, H., Matsuura, Y., Kishimoto, T. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc. Natl. Acad. Sci. USA 117(36): 22351-22356, Sep. 2020.